Revenue and Adjusted EBITDA Growth
Total revenue for Q1 2026 was $236.1 million, a 15% increase compared to Q1 2025. Adjusted EBITDA more than doubled to $17.6 million from the previous year.
Record Census and Participant Growth
The census grew to an all-time high of 7,890 participants, reflecting a 9.4% increase year-over-year and a 1.9% increase quarter-over-quarter.
Positive Net Income and Improved Margins
Net income was $7.7 million, compared to a net loss of $5.7 million in Q1 2025. The center-level contribution margin increased to 21.8%, a rise of approximately 320 basis points from the previous quarter.
Successful In-House Pharmacy Transition
The transition to in-house pharmacy services contributed to reduced pharmacy expenses and improved cost management.
Leadership and Organizational Enhancements
New leadership appointments, including Dr. Paul Taheri as Chief Medical Officer and Meredith Delk as Chief Administrative Officer, aim to strengthen operations and continue organizational growth.